Search
for
Sort by
Research 30 of 1000+
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report
- Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- Holistic management of Alopecia areata (~Indralupta) using Pracchana karma with derma-roller and Ayurveda intervention: A case report
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Not just thinning: A case of alopecia universalis after mild COVID-19
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Alopecia Areata Treated with Homoeopathic Preparation of Phosphorus: Two Evidence-Based Case Reports
- Alopecia Areata
- Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation
- Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
- Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
- Efficacy and Safety of Topical Tofacitinib for the Treatment of Alopecia Areata